Akebia Therapeutics, Inc. (AKBA) dividends
AKBA on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Akebia Therapeutics, Inc. dividend: key facts
Own Akebia Therapeutics, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next AKBA dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Akebia Therapeutics, Inc.: Regulation FD disclosure (8-K)16 Nov 2026 · SEC EDGAR
- Akebia price target lowered to $4 from $6 at H.C. Wainwright6 Nov 2026 · TheFly
H.C. Wainwright lowered the firmâs price target on Akebia (AKBA) to $4 from $6 and keeps a Buy rating on the shares following the Q3 report.
- Akebia price target lowered to $3 from $4 at BTIG6 Nov 2026 · TheFly
BTIG analyst Julian Harrison lowered the firmâs price target on Akebia (AKBA) to $3 from $4 and keeps a Buy rating on the shares. Vafseo underlying demand remains healthy despiteâ¦
- Akebia reports topline results from VOCAL trial5 Nov 2026 · TheFly
Akebia (AKBA) announced topline results from VOCAL, an open-label trial to evaluate the efficacy and safety of three times per week, or TIW, dosing of vadadustat compared to the currentâ¦
- Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights5 Nov 2026 · GlobeNewsWire
Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025
- Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin5 Nov 2026 · GlobeNewsWire
WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, toda...
- Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights29 Oct 2026 · GlobeNewsWire
WALTHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2026, on Th...
- U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week26 Oct 2026 · GlobeNewsWire
Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Vadadustat demonstrated a clinically meaningful ...
Insufficient verified data for a financial-health score
Dividend data and price last updated 18 Nov 2026.